AbSci will integrate the Denovium Engine into its drug discovery and manufacturing cell line development capabilities and build near-term synergies using AI deep learning to better predict relevant variants and cell line characteristics for each new project.

AbSci aims to make an in silico biologic drug discovery and cell line development platform to bring next-generation therapies to market at unprecedented speeds.

Denovium's engine is a multidimensional deep-learning model built to interpret, categorize, predict, and evolve function and behavior of proteins. The platform has been trained on more than 100 million proteins and across 700,000 descriptive protein parameters. AbSci plans to further train the engine on its proprietary internally generated multidimensional protein characterization datasets that include elements of protein functionality, expression, and manufacturability.

"Combining that design power with our proprietary data from our Protein Printing platform, AbSci can create a new gold standard for drug discovery and cell line development for next-generation biologics while at the same time allowing for creation of novel biologies previously unattainable," said Sean McClain, founder and CEO of AbSci.

The financial details of the acquisition were not disclosed.